1. In Vivo
  2. >>Business Strategy

Doubling Pharma Value With Data Science

 
• By Sam Marwaha, Michael Ruhl, and Paul Shorkey

A once-in-a-generation opportunity has opened to digitally redesign a core part of the biopharma business. Capturing the opportunity requires vision and leadership; it’s not about the technology.

IV1803_BCG-DNA_371573425_1200.jpg

The digital era is revolutionizing the health care industry, but pharma's approach to product development and market access has remained relatively unchanged. Pharma companies have been experimenting with digital technologies and analytics-driven pilots, but instead of seeing meaningful impact on productivity and access, they’re watching cost and complexity go up. As one pharma executive put it, “It’s like lasagna. We just keep adding ever more layers of cost and taking nothing out.”

The reality is that digital technologies won't transform a business if its operating model isn't designed to accommodate digital innovation....

Welcome to In Vivo

Create an account to read this article

Already a subscriber?

More from Business Strategy

Dealmaking Quarterly Statistics, Q2 2025

 
• By Maureen Riordan and Deanna Kamienski

During Q2, biopharma merger and acquisition deal value reached $24.6bn and drew in $60.7bn in potential deal value from alliances. Device company M&A values reached $223m, while in vitro diagnostics and research tools players’ M&A activity totaled $802m.

Infographic: How Big Pharma Is Scaling Beyond Pilot AI Projects

 
• By David Wild

Pharma leaders are shifting from AI pilots to enterprise-scale deployment, favoring external partnerships for efficiency gains while maintaining tight control over sensitive clinical data.

When VC Steps Back: Finding Alternative Biotech Funding

 
• By Jo Shorthouse

The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 
• By Anabel Costa-Ferreira

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

More from In Vivo

Podcast: Tevard CEO Sees Hope For His Daughter In Company’s tRNA Platform

 
• By David Wild

Tevard Biosciences CEO Daniel Fischer discusses how engineered suppressor tRNAs overcome nonsense mutations, restoring full-length protein production to treat rare genetic diseases like Dravet syndrome.

Deals In Depth: July 2025

 
• By Deanna Kamienski and Maureen Riordan

Six $1bn+ alliances were penned in July, and two exceeded $2bn.

Execs On The Move: July 2025

 
• By In Vivo Team

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.